Purpose of review Eating Disorders are psychiatric disorders associated with a high risk for low bone mineral density (BMD) and fractures. Low BMD is a consequence of undernutrition, changes in body composition, and hormonal alterations. This review summarizes recent findings regarding novel strategies for assessing bone outcomes in patients with eating disorders, factors contributing to altered bone metabolism, and possible therapeutic strategies.
INTRODUCTION
Eating disorders have the highest mortality among psychiatric disorders, with the most studied eating disorders being anorexia nervosa and bulimia nervosa [1] . Eating disorders, specifically anorexia nervosa, are also associated with multiple neuroendocrine disruptions and low bone mineral density (BMD) [2] . Excessive food restriction, particularly during adolescence, can disrupt attainment of peak bone mass, resulting in long-term skeletal complications [3] . The diagnostic and statistical manual of mental DSM-5 criteria for anorexia nervosa and bulimia nervosa diagnosis is summarized in Table 1 [4] .
In a community sample of adult women with anorexia nervosa, 93% had BMD 1 SD below the population mean and approximately 40% had BMD 2.5 SD below the population mean at one or more sites, meeting criteria for secondary osteoporosis [5, 6] . Adolescents with anorexia nervosa are also at risk for low BMD, with approximately 50% reported to have BMD 1 SD below the mean at one or more skeletal sites [7] . Approximately, 30% of adolescent girls, as well as adult women with anorexia nervosa, report sustaining a fracture [6, 8] . Of note, both subtypes of anorexia nervosa, the restricting subtype and the binge-purge subtype are associated with reductions in spine BMD and increased fracture risk compared to controls [9] . Anorexia nervosa-R and anorexia nervosa-binge purge are also associated with lower total body, hip, and limb BMD, even in population-based samples, as shown in a longitudinal study from the UK [10 & ]. Furthermore, in addition to anorexia nervosa, normal weight bulimia nervosa patients have lower spine BMD than controls, suggesting that weight loss alone may not explain the deleterious effects of eating disorders on bone [11] .
The importance of developing efficacious treatments to increase BMD and reduce fracture risk in eating disorders is highlighted by the persistence of long-term deficits in BMD despite recovery from the eating disorders. Femoral neck BMD was reported to be lower in women with a past history of anorexia nervosa than controls, despite being in recovery for a mean of 21 years [12] . Maximal voluntary ground reaction force has been used as a measure of bone strength in women who had recovered from anorexia nervosa for approximately 27 years. Recovered women had lower volumetric BMD (vBMD) and maximal strength than healthy controls, suggesting that BMD deficits in anorexia nervosa persist despite recovery [13] . A previous population-based retrospective study found the cumulative incidence of fracture to be 57% in women with a history of anorexia nervosa, highlighting the significant pain and disability endured by this group [14] .
ASSESSMENT OF BONE OUTCOMES, INCLUDING USE OF NOVEL TECHNIQUES

Biochemical markers of bone turnover
Surrogate (or biochemical) bone turnover markers provide evidence of the rate of bone formation and resorption in women with anorexia nervosa compared with healthy women. Commonly reported bone formation markers include osteocalcin, bonespecific alkaline phosphatase and the N-terminal propeptide of type 1 procollagen. Commonly reported bone resorption markers include deoxypyridinoline, C-telopeptide, and N-telopeptide. Adolescents have decreases in biochemical markers of both bone formation and resorption, indicative of reduced bone turnover [15] , whereas adults with anorexia nervosa have decreased bone formation and increased resorption markers, indicative of an uncoupling of bone turnover, both of which lead to reductions in BMD [2] . Osteoclasts and osteoblasts facilitate bone modeling and remodeling in adolescents, and bone remodeling in adults, and extreme weight loss may disrupt this process in anorexia nervosa.
Osteoprotegerin (OPG) and soluble receptor activator of nuclear factor kappa-B (RANK) ligand (sRANKL) levels and their ratio provide evidence of the ongoing drive for bone resorption [16] . RANKL is secreted by stromal precursor cells and osteoblasts, and these cells also secrete OPG, the soluble decoy receptor for RANKL. When RANKL binds to RANK (expressed on osteoclast precursors and osteoclasts), it activates osteoclast activation and function and reduces osteoclast apoptosis, thus increasing bone resorption. OPG, in contrast, by binding to RANKL prevents it from binding to RANK, and thus reduces osteoclast activation and function and increases osteoclast apoptosis, leading to decreased resorption. Therefore, the lower the ratio of OPG to sRANKL, the greater is the drive for bone resorption. Transforming growth factor b, a multifactorial cytokine, correlates positively with the OPG/sRANKL ratio. In anorexia nervosa, OPG and sRANKL levels are elevated, but the ratio of OPG to sRANKL is reduced. Transforming growth factor-b secretion is reduced in anorexia nervosa, which may compromise the mechanism compensating for bone remodeling [17] . Omentin-1, secreted by visceral adipose tissue, is increased in anorexia nervosa, and has recently been suggested to exert a negative effect on bone remodeling [18] , independent of menstrual status. This effect is greater in younger, premenarcheal girls [19] .
Assessment of areal bone density and hip structural analysis
Dual X-ray absorptiometry (DXA) is a well recognized instrument to evaluate fracture risk in postmenopausal women, although the predictive capability for fracture risk in premenopausal women with anorexia nervosa is not fully established [20] . Areal BMD (aBMD) is a two-dimensional measurement, and its assessment is affected by changes in bone size, maturation, and body composition. Adolescent and adult women with anorexia nervosa have low aBMD at multiple sites; however, this does not always correlate with fracture prevalence [21] .
In addition to BMD measured by DXA, bone geometry and microarchitecture and its mechanical
KEY POINTS
Not only anorexia nervosa, but also bulimia nervosa results in lower BMD compared to controls.
Promising treatment strategies include physiological estrogen replacement (rather than oral contraceptives) in adolescent girls with anorexia nervosa, and bisphosphonates, as well as TPT, in adult women with anorexia nervosa.
The association between resting energy expenditure, marrow adipose tissue, and cold activated brown adipose tissue with BMD and bone structure in anorexia nervosa is discussed.
load distribution are important determinants of bone strength. DXA allows reporting of hip structural analysis (HSA), which reveals the structural geometry of the proximal femur at the narrow neck, intertrochanteric and femoral shaft, with one study reporting that the majority of HSA-derived parameters were impaired in anorexia nervosa, and superior in obese/overweight women in comparison to healthy controls [22] .
Assessment of volumetric bone mineral density, bone size, and structure Anorexia nervosa has negative effects on vBMD, and bone size and structure, and these alterations may explain fracture risk independent of aBMD [21] . The primary tools for assessing vBMD and bone structure are quantitative computed tomography (QCT) and more recently, high-resolution peripheral QCT (HRpQCT). QCT allows assessment of both bone geometry and vBMD, which have been reported to account for differences in bone strength in postmenopausal women, even without significant differences in aBMD [23] . Further, HR-pQCT allows assessment of bone microarchitecture. Finite element models of bone can be created from in-vivo three-dimensional QCT images, and more recently from HR-pQCT images [24] [25] [26] , and allow bone strength estimation.
At the distal radius, girls with anorexia nervosa have lower total and trabecular vBMD, lower cortical area and thickness, and increased cortical porosity and trabecular separation compared with controls, as assessed using HR-pQCT [7] . Failure load and stiffness, estimated by microfinite element analysis, are 15 and 16% lower at the distal radius in girls with anorexia nervosa, indicative of reduced strength. This effect remained after controlling for bone age, height and adjusting for radial aBMD [7] . Deficits in cortical thickness and trabecular number have been reported in adults with anorexia nervosa at the distal radius, with cortical deficits being related to age of onset of the eating disorders [27] . Furthermore, flat-panel volume computed tomography (CT) is effective in evaluating trabecular structure, including apparent bone volume fraction, apparent trabecular thickness, and apparent trabecular number, all of which are reduced in adult women with anorexia nervosa compared with controls at the distal radius [28] . Fewer data are available for the distal tibia. However, one study assessed the distal tibia using pQCT, and reported lower trabecular, but higher cortical vBMD, in young women with anorexia nervosa compared with controls. Anorexia nervosa girls in this study had a mean percentage ideal body weight of 91%, and thus were not as low weight as in other studies [29 & ]. Estimated vertebral strength, derived from integral vBMD values from QCT scanning is lower in low-weight anorexia nervosa compared with controls, and intermediate in atypical anorexia nervosa [30 & ]. Both measures were associated positively with BMI and inversely with the duration of amenorrhea. Another study assessed vertebral bone texture using a low-dose single-section quantitative CT of the lumbar vertebra 4 vertebral body with use of a calibration phantom, and reported altered bone texture in women with anorexia nervosa, which was associated with lowest lifetime body weight and duration of amenorrhea [31] .
FACTORS MEDIATING REDUCTIONS IN BONE MASS IN PATIENTS WITH EATING DISORDERS
Energy status and body composition
Resting energy expenditure has been linked to bone remodeling, glucose homeostasis, and adipokines, highlighting the importance of preventing energy deficiency to limit hormonal alterations and disruptions in bone mineralization in anorexia nervosa [32 && ]. Numerous studies demonstrate that lower body weight and particularly lower lean body mass are important determinants of deleterious bone outcomes in eating disorders. Both subtypes of anorexia nervosa are associated with reductions in spine BMD and increased fracture risk compared to controls [10 & ]. The subtypes of anorexia nervosa are also associated with lower total body, hip, and limb BMD, even in population-based samples, as shown in a recent longitudinal study from the UK [10 & ]. Furthermore, normal weight bulimia nervosa patients have lower spine BMD than their healthy counterparts, suggesting that weight loss alone may not explain the deleterious effects of an eating disorders on bone [11] .
Lower fat mass (particularly subcutaneous fat) may also play a role, given that this is a source of leptin secretion, a hormone with bone anabolic effects. Recent studies have moved to assessing nontraditional fat stores in anorexia nervosa, including marrow adipose tissue and cold activated brown adipose tissue (BAT). A common stromal progenitor stem cell in marrow differentiates into either an osteoblast or adipocyte depending on the marrow energetic and hormonal milieau, and marrow adipose tissue is higher in women with anorexia nervosa compared with controls, associated with lower BMD measures [33] . The degree of bone marrow fatty acid saturation correlates inversely with BMD, suggesting that saturated lipids may have negative effects on BMD in anorexia nervosa [34] . This inverse relationship was also observed in healthy individuals [35] . Women with anorexia nervosa have low cold-activated BAT, which may be because of impaired BAT thermogenesis and an adaptive mechanism to reduce energy expenditure in this state of energy deficit. Young women with BAT have higher BMD and lower preadipocyte factor-1 (Pref-1; a negative regulator of osteoblastogenesis in the marrow) compared with women without BAT [36] . Given that women with anorexia nervosa have higher Pref-1 levels than controls, which correlate inversely with bone density [36] , BAT may be involved in regulation of stem cell differentiation toward the bone lineage at the expense of adipogenesis [37] .
Nutrient intake
A recent study found that just four in 30 anorexia nervosa participants take multivitamin supplements, and one in 30 take calcium supplements [38] . Low calcium levels have been associated with hypogonadal states known to affect bone metabolism, and vitamin D receptors are closely linked to osteoblast function [39] . In a recent cross-sectional study, serum 25-hydroxy-vitamin D below 50 nmol/ l was positively associated with spine BMD Z-scores in women with anorexia nervosa, and also with increased alkaline phosphatase levels, suggesting an adaptive osteoblastic reserve [40] . To date, there is no evidence to suggest that calcium or vitamin D supplementation increases BMD in anorexia nervosa, and no correlation between calcium or vitamin D intake and BMD in adolescents with anorexia nervosa [40] . However, a treatment goal is to optimize intake of these nutrients in adolescent and adult women with eating disorders.
Vitamin K supplements may reduce loss of BMD in women with anorexia nervosa, with adequate vitamin K intake being required to achieve g-carboxylation of osteocalcin. Serum undercarboxylated osteocalcin levels are negatively correlated with vitamin K intake in anorexia nervosa [41] . Furthermore, vitamin K deficiency was more pronounced in anorexia nervosa binge-purge subtype than anorexia nervosa restricting subtype, suggesting that further study into vitamin K deficiency in other eating disorders diagnoses is necessary [42] .
Alterations in endocrine axes
In addition to weight loss, bone is affected by the various neuroendocrine alterations observed in women with eating disorders.
Hypothalamic-pituitary-gonadal axis
Amenorrhea has now been removed from the revised DSM-5 criteria for the diagnosis of anorexia nervosa; however, hypothalamic amenorrhea is still common in anorexia nervosa. Suppression of the hypothalamic-pituitary-gonadal axis preserves energy in a state of semistarvation by preventing energy being diverted toward reproduction and maintenance of a growing fetus [43] . Estrogen typically inhibits osteoclastic bone resorption [44] , and may increase bone formation as well by inhibiting sclerostin and Pref-1 [45, 46] . Estrogen deficiency is closely linked to amenorrhea in anorexia nervosa, although bone resorption is higher in adult amenorrhea women with anorexia nervosa than postmenopausal women [47] , suggesting that other factors also contribute to increased bone resorption in anorexia nervosa. Testosterone is another gonadal hormone believed to have a positive effect on bone through its aromatization to estradiol (E2), and also through its direct bone anabolic effects [48] . Females with anorexia nervosa have lower testosterone levels than controls, associated with lower BMD measures.
Hypothalamic-pituitary-adrenal axis
Adolescents and young women with anorexia nervosa have higher cortisol levels than controls, which is also deleterious to bone. High cortisol levels have an inhibitory effect on the hypothalamic-pituitarygonadal axis and growth hormone (GH)-insulin like growth factor-1 (IGF-1) axes, impair calcium absorption from the gut, and inhibit OPG and increase RANKL secretion. They may also have a direct inhibitory effect on osteoblasts.
Growth hormone-insulin-like growth factor-1 axis Anorexia nervosa is associated with a nutritionally acquired GH resistance with lower IGF-1 and higher concentrations of GH than observed in controls. Reductions in IGF-1 correlate with a reduction in bone formation markers and lower spine BMD [49] and endogenous IGF-I levels predict bone microarchitecture independent of BMI in women with anorexia nervosa [35] . In anorexia nervosa, higher GH levels are associated with lower levels of IGF-1 and fibroblast growth factor 21, a hormone produced in the liver which may play a role in the mechanism of GH resistance in anorexia nervosa. Fibroblast growth factor 21 levels are inversely associated with estimates of radial bone strength (stiffness and failure load) in anorexia nervosa [50] .
Appetite regulating hormones
Appetite regulating hormones such as leptin (an anorexigenic hormone), ghrelin (orexigenic), and peptide tyrosine tyrosine (PYY; anorexigenic), are altered in anorexia nervosa. Leptin and ghrelin are bone anabolic, whereas PYY inhibits osteoblast differentiation. Compared to controls, adults and adolescents with anorexia nervosa have lower leptin levels, a potential resistance to ghrelin with higher ghrelin levels [51] and an increase in PYY [52] . In healthy adolescents, higher ghrelin concentrations predict higher BMD. However, this association is not observed in anorexia nervosa, suggesting a resistance to ghrelin [53] . Lower leptin and higher PYY levels are associated with lower levels of bone turnover markers and lower BMD [43] .
Other hormones and neurotransmitters
Oxytocin has anorexigenic and bone anabolic effects [54] and oxytocin levels are lower in women with anorexia nervosa than controls (likely an adaptive response), associated with lower BMD [55] .
Serotonin (5-hydroxytryptamine) receptors are found on osteoblasts, osteoclasts, and osteocytes [56] , and an inverse relationship exists between serum serotonin levels and femoral neck, total and trabecular vBMD in healthy women [57] . However, in a cross-sectional analysis of serum serotonin, BMD, and bone metabolism markers, a negative relationship was noted between serum serotonin and bone turnover markers [58 & ], suggesting that this warrants further study. At least one study has demonstrated that a longer duration of use of selective serotonin reuptake inhibitors is associated with lower BMD in young women with anorexia nervosa even after controlling for the duration since diagnosis and duration of amenorrhea [59] .
IMPACT OF DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL IV VS. DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL 5-BASED DIAGNOSIS OF EATING DISORDERS ON BONE OUTCOMES
Schorr et al. [60 && ] have reported that despite liberalizing diagnostic criteria, many women diagnosed with anorexia nervosa and atypical anorexia nervosa using DSM-5 criteria have low BMD. In this study, BMD Z-scores were less than À1.0 in 78% of DSM-IV, 82% of DSM-5, and 69% of atypical anorexia nervosa. Mean Z-scores were comparably low in women meeting diagnostic criteria for anorexia nervosa per DSM-IV and DSM-5, intermediate in atypical anorexia nervosa, and highest in normalweight controls. Lack of prior low weight or amenorrhea was not protective against bone loss. The authors concluded that the deleterious effect of EDs on BMD extends beyond those with current low weight and amenorrhea.
In another study, Kandemir et al. [61 && ] evaluated the clinical utility of existing cut-offs for low weight in adolescents and young adults with eating disorders, as well as severity criteria for low weight by determining which are most strongly associated with risk for low BMD. Among severity categories, BMI Z-scores had the greatest utility in assessing the degree of malnutrition in adolescent girls that corresponded to lower BMD.
TREATMENT STRATEGIES
The first line of management of low BMD in anorexia nervosa is weight gain and resumption of menses. In addition, a number of treatment strategies have been investigated in adolescent and adult women with anorexia nervosa, including oral contraceptives, physiologic estrogen replacement as the transdermal patch, testosterone replacement, dehydroepiandrostenedione (DHEA) and recombinant human (rh)IGF-1 (in combination with estrogenprogesterone combination pills), bisphosphonates, Table 2 . Possible treatment strategies to increase bone mineral density in anorexia nervosa An alternative to MPA is micronized oral progesterone 100-200 mg given daily for 10-12 days every month Testosterone replacement Testosterone levels are low in adolescent and adult women with AN compared with controls. Testosterone is known to inhibit bone resorption through its aromatization to estradiol (E2), and also has direct bone anabolic effects A trial investigating administration of testosterone (as the low dose testosterone patch) showed that this strategy was not effective in increasing bone density in adult women with AN over 12-months [48] Dose used: 150 mg testosterone patch; dose titrated to maintain testosterone levels in the upper half of the normal range for women DHEA administration One study has reported low DHEA levels in adolescent and young adult women with AN. DHEA is a precursor for both estrogens and androgens, and may inhibit osteoclastic bone resorption indirectly through mechanistic links to estrogen receptors Oral DHEA given with an oral estrogen-progesterone combination contraceptive pill has been reported to maintain BMD Z-scores in adolescents and young adult women with AN over 18 months, but is not recommended as a treatment option in isolation [45, 64] and teriparatide (TPT). Potential therapeutic options and the rationale for these treatment strategies, are summarized in Table 2 . Estrogen-progesterone combination pills providing estrogen doses of 20-35 mg ethinyl estradiol per day, do not improve BMD in this condition [45, 62] , likely because of the IGF-1 lowering effect of oral estrogen. In contrast, physiologic estrogen replacement as the 100 mg transdermal 17 b estradiol patch, known to bypass first pass hepatic metabolism, increases spine and hip BMD in adolescent girls with anorexia nervosa. Girls with anorexia nervosa receiving physiologic estrogen replacement (with cyclic progesterone) for 18 months had greater increases in BMD than anorexia nervosa girls on placebo, with bone accrual rates approaching that observed in normal-weight controls (P ¼ 0.044 and 0.040, respectively) [63] . This may reflect either the type of estrogen used (17 b estradiol vs. ethinyl estradiol), or the administration method (transdermal vs. oral), or both. Data are lacking regarding the effect of oral 17-b estradiol on bone outcomes in anorexia nervosa. Of note, although BMD increased significantly in the anorexia nervosa girls, catch-up did not occur, likely because other hormone deficiencies/excess were not addressed.
A combination of oral estrogen-progesterone and DHEA (50 mg daily) for 18 months in young women with anorexia nervosa was reported to increase cortical thickness, improve femoral crosssectional area and selection modulus (measured by HSA) [44] , with a maintenance of DXA measures of BMD Z-scores over the study duration [45, 64] .
Weight gain in women with anorexia nervosa correlates with increases in testosterone levels, which in turn correlate with an increase in BMD [68] . However, low-dose transdermal testosterone administration over one year did not increase BMD in adult women with anorexia nervosa [48] .
Short-term rhIGF1 replacement increases bone formation markers in adults and adolescents with anorexia nervosa [69, 70] , and when combined with an estrogen-progesterone combination pill in a placebo-controlled trial, was found to increase spine and hip BMD in adult women with anorexia nervosa compared with controls who received neither (1.8% AE 0.8% vs. À1.0% AE 1.3% at the spine, P < 0.05) [65] . An ongoing randomized controlled trial at Massachusetts General Hospital aims to investigate if rhIGF1 combined with transdermal E2 replacement (vs. transdermal E2 alone) is effective in increasing BMD Z-scores in adolescents with anorexia nervosa, and if this enables the 'catch-up' effect to increase BMD to a level comparable to healthy controls.
Bisphosphonates are not recommended to women with eating disorders of reproductive age AN, anorexia nervosa; BMD, bone mineral density; RCT, randomized controlled trial; rhIGF-1, recombinant human insulin-like growth factor; TPT, teriparatide.
due to limited knowledge of their long-term efficacy. Following 1 year of administration of alendronate (10 mg daily) to adolescents with anorexia nervosa, vBMD of the femoral neck was higher in those receiving alendronate compared to placebo controls [66] . However, no effect was observed at the spine. In adults with anorexia nervosa, risedronate (35 mg weekly) has been shown to increase spine BMD over 1 year [48] . TPT (human PTH) is a bone anabolic agent with proven antifracture efficacy in postmenopausal women and men with osteoporosis. Shibli-Rahhal et al. [67] found a 21% increase in BMD and no reoccurrence of fractures following 2 years or TPT in a 52-year old anorexia nervosa patient. Fazeli et al. confirmed these findings with a placebo-controlled randomized controlled trial and found a 6-10% increase in spine BMD after 6 months of TPT treatment (20 mg daily) in older women with anorexia nervosa [71] . However, safety concerns associated with the use of TPT derive from the increased risk of osteosarcoma in rodent studies, suggesting that TPT may be unsuitable for young women and adolescents.
CONCLUSION
A better understanding of the neuroendocrine disturbances associated with eating disorders, particularly in anorexia nervosa, and their impact on BMD and bone microarchitecture provides an opportunity to explore future interventions in this population. Recent advances in assessment techniques for aBMD, vBMD, and bone microarchitecture have led to a better characterization of bone compromise in women with eating disorders. Physiologic estrogen replacement has been successful in increasing BMD in young women with anorexia nervosa, although complete 'catch-up' does not occur. Bisphosphonates, such as risedronate, increase BMD in adult women with anorexia nervosa but should be used with caution in women of reproductive age. The positive effects of TPT suggest a promising future bone anabolic treatment for low BMD in older women with anorexia nervosa; however, this is not currently an option in young women and adolescents. Trials of rh-IGF1 in combination with estradiol are ongoing in adolescents to determine whether this combination therapy allows for 'catch-up' to occur in anorexia nervosa. The significant, long term, deleterious impact of eating disorders on bone health highlights the importance of adequate and timely assessment and early intervention.
